Molecular genetic characteristics of gastric cancers from the surgeon’s point of view by Dubinina, V. G. et al.
 592 
Dubinina V. G., Mashukov A. A., Lukyanchuk O. V., Bilenko A. A., Zgura A. N., Raciborsky D. V., Lee S. N.  Molecular genetic 
characteristics of gastric cancers from the surgeon’s point of view. Journal of Education, Health and Sport. 2016;6(11):592-621. eISSN 2391-
8306. DOI http://dx.doi.org/10.5281/zenodo.200394 
http://ojs.ukw.edu.pl/index.php/johs/article/view/4063 
 
 
 
 
The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 755 (23.12.2015). 
755 Journal of Education, Health and Sport eISSN 2391-8306 7 
© The Author (s) 2016; 
This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland 
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, 
provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License 
(http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial 
use, distribution and reproduction in any medium, provided the work is properly cited. 
The authors declare that there is no conflict of interests regarding the publication of this paper. 
Received: 02.11.2016. Revised 22.11.2016. Accepted: 30.11.2016. 
 
MOLECULAR GENETIC CHARACTERISTICS OF GASTRIC CANCERS FROM THE 
SURGEON’S POINT OF VIEW 
  
V. G. Dubinina1, A. A. Mashukov2, O. V. Lukyanchuk2, A. A. Bilenko1, A. N. Zgura2,  
D. V. Raciborsky2, S. N. Lee2 
 
1Odessa National Medical university 
2Odessa Regional Oncology center 
 
Summary 
A study on the expression of oncoproteins in stomach` carcinomas, has been turned into a 
real research basically due to the abundance of results and their comprehensive interpretations. The 
study carried out on the abdominal onco-surgical department of Odessa Regional Oncology Center, 
included a study of 188 patients operated on for gastric cancer (GC) between 2007-2011. In all 
cases was performed the so-called lymphadenectomy for the principal reason of extensive 
preventive biopsy of visually unchanged lymph nodes. We spend a multivariate analysis of 
interactions between the expression of oncoproteins  p53, VEGFR-3, erbB2, Ki67 and micro 
involvement of tumor vasculature (ly, v), the local growth (T), the presence of residual tumor tissue 
(the R), the degree of tumor differentiation (the G) the degree of regional lymph nodes involvement 
(N) and type of infiltration (Inf α, β, Inf Υ). 
Keywords: Stomach cancer, Immunohistochemistry and Oncoproteins. 
 
Gastric cancer (GC) genetical characteristic study shows largely speculative, theorized 
character, remaining "armchair science". It’s clinical significance is revealed mostly in predicting 
chemotherapy or screening for therapeutic and preventive measures respectively. 
Significant expression her2 \ new -  trastuzumab, lapatinib administration; EGRF mutated 
gene – prescribing of Erlotinib, Gefitinib, Afatinib; translocation of EML4-ALK - Krizotinib; 
translocation of BCR-ABL - Imatinib; "Wild" type tyrosine kinase gene K-RAS and N-RAS - 
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predictors of efficacy of Cetuximab and Panitumumab , a serine-threonine kinase B-RAFwt - 
Vemurafenib; the presence of gene mutations CDH-1, BRCA-1, MLH1 , MLH3, MSH-2, MSH-6, 
PMS-1 - inherited gastric cancer predisposition, etc. In the processing - novel theraputical "targets": 
COX-2 inhibitors (there are reports on the effectiveness of Aspirin when mutated PIK3CA), 
metalloproteinases , telomerase, farnesyltransferase. 
COX-2 (COX-2) along with VEGFR-3 (VEGF-C) is considered to be a prognostic factor in 
gastric cancers. There are a number of reports on the prognostic role of HER-2 marker in gastric 
cancers [26, 27, 28, 29]. 
ERCC1 expression is referred to as a predictor of sensitivity to Oxaliplatin [32] in stomach 
cancer. 
The level of mRNA BRCA-1 gene in gastric cancer in clinical trials had a negative 
correlation with respect to the sensitivity of GC to Cisplatin and positive - with respect to sensitivity 
to Taxanes. There is a case described in the medical literature of successful cure BRCA-1 positive 
metastatic gastric cancer with multiple liver lesions by Docetaxel [44], see Fig. 1. 
Jong Gwang Kim [18] described the following target molecules, expired in advanced gastric 
cancer (2013): 
1. A monoclonal antibody to the receptor EGFR (Cetuximab / Panitumumab). 
2. Tyrosine Kinase Inhibitor EGFR (Erlotinib / Gefitinib). 
3. Monoclonal antibody to the receptor Anti-HER-2 mAbs (Trastuzumab). 
4. tyrosine kinase inhibitors of HER-2 TKI (Lapatinib) 
5. Monoclonal antibodies to growth factor Anti-VEGF (Bevacizumab). 
6. The monoclonal receptor antibody Anti-VEGFR (Ramucirumab). 
7. Inhibitors of tyrosine kinase receptor VEGFR (Sunitinib / Sorafenib / Cediranib / 
Apatinib). 
8. Everolimus –mTOR inhibitor (mammalian target of Rapamycin), Akt pathway. 
9. Onartuzumab - monoclonal antibody to hepatocyte growth factor receptor (HGFR), 
encoded by the c-Met oncogene. 
And some other molecules, are still at the stage of clinical trials. Ongoing multicenter study 
KEYNOTE-012 (1b phase), dedicated to the prospects of Pembrolizumab immunotherapy in 
patients with advanced PD-L1 + GC [41]. 
Genetic testing for the individualization program and screening of healthy people  should be 
done just once per life (full-genetic sequencing). On the contrary, tumor cell population is 
heterogeneous, there is a subpopulation of cells in various stages of  cell cycle, with different 
sensitivity to chemotherapeutic regiments [7]. Differences between chemo-naive and pretreated 
cancers (after formation of drug resistance) motivated us to obtain repeated biopsies and promote 
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the gradual implementation of the immunohistochemical study of  biopsies of tumors [5], including 
gastric cancer. 
 
 
 
 
 
Figure 1. Complete clinical and instrumental regression in a patient with the BRCA-1 
positive metastatic gastric cancer with liver disease on the background of Docetaxel therapy. 
 
The introduction into clinical practice the molecular classification of gastric cancer [9], such 
as what is widely used in breast cancers, makes this study direction actualistic. 
It was impossible in one study to consider all variants of protein molecules that are 
expressed in stomach cancer [10, 11]. Taking into account the new genetic classification, the four 
most well-known affordable oncoproteins were distinguished. Genetic classification of gastric 
cancer includes four types of tumors namely: 
1. The genetically stable stomach cancer. 
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2. Microsatellite-unstable stomach cancer. 
3. Chromosomal-unstable stomach cancer. 
4. Epstein-Barr virus-associated gastric cancer. 
 
 
Fig. 2. Immunohistochemical staining for p53 Protein (DO-7) - oncoprotein expression level 
with a molecular weight of 53 kDa here 80%. 
 
For example, chromosomally unstable gastric cancer (CUN) shows amplification of the 
TP53 gene (short arm of chromosome 17) and oncogene her2\new (long arm of chromosome 17) - 
respectively, for the study proteins p53 and erbB2 (CD 340) are eligible, see Figures №2 and №3. 
Chromosome unstable gastric cancer (CUN) takes approximately 50% of all malignant epithelial 
tumors of the stomach, so the study of these two markers appears to be very effective. 
 
 
Fig. 3. Immunohistochemical staining for Her-2neu (with 2-erB-Oncoprotein) - 3+. 
 
Three other genetic forms of gastric cancer: microsatellite unstable cancer (MSU) [16, 38, 
43]; genetically stable cancer ("cancer of Napoleon" [36] - CDH-1 induced, the protein product is 
E-cadherin), or as it is called "cadherin" gastric cancer; and Epstein-Barr (EBV) virus-induced 
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gastric cancer [13, 14, 15, 43], wherein the gene expression is observed from the other receptor 
signaling cascade epidermal EGRF, - PI3K or PIK3CA, - phosphoinositol-3-kinase. 
The most frequently observed mutations at microsatellite unstable gastric cancer is the so-
called "silencing» of the main DNA repair genes - MLH1. Turn off other repair genes - MLH3, 
MSH2, MSH3, MSH6, PMS1, PMS2 (although, strictly speaking, all suppressor genes considered 
repair genes such as BRCA) is less common. 
When CUN often occurs intestinal form of gastric cancer by Lauren classification, with GS 
(genetically stable variant) - diffuse type of gastric cancer. It is believed that due to low 
concentration or defectiveness of "intercellular cement" E-cadherin in diffuse gastric cancer comes 
a fast hematogenous dissemination. MSI is associated with hypermethylation [42, 43] of the most 
active regions of DNA - CpG-islands (spots where the cytosine is preceded by a guanine). There are 
some reports about the greater sensitivity of this genetic categories to irinotecan-based 
chemotherapy regimen. EBV-cancer most often affects the antral part of stomach. 
Genetic analysis of MSI alone seems to be used as a surgical predicting factor, because 
classical chemotherapy, particularly in elderly patients, in the case of MSI isn’t promising [50]. 
This type of tumors exhibit a local pronounced immunosuppressive activity [48, 49]. Therefore, as 
EBV gastric cancer, MSI gastric cancer is considered promising for the novel immunological drugs 
(PD-L1 / PD-L2 namely Ipilimumab, Nivolumab, Pembrolizumab) administration [39]. 
Already available monoclonal antibodies for a broader study of microsatellite unstable 
gastric cancer patients [57]: 
 
Mismatch Repair Protein (MLH1) - antibody ES05 
Mismatch Repair Protein (MSH2) - antibody 25D12 
Mismatch Repair Protein (MSH6) - antibodies PU29 
Mismatch Repair Protein (PMS2) - antibodies M0R4G. 
 
Imyanitov et al. [50] comments on the importance of MSI analysis to chemotherapy and its 
particular importance for surgical oncology: 
1. Most of the microsatellite-unstable carcinomas (MSI-H colorectal cancer, gastric cancer, 
ER belong to Lynch syndrome) are sporadic. [51, 52]. 
2. Hereditary colorectal cancer (CRC) affect relatively young subjects, the sporadic cases of 
MSI-H (H - high, high level of volatility) accumulate in elderly patients. 
 Hereditary cancers occur because of mutational inactivation MLH1, MSH2, PMS2 or MSH6 
whereas sporadic MSI-H tumors typically arise as a result of gene promoter methylation of  MLH1, 
which may be due to widespread abuses, epigenetic regulation ("methylator phenotype"). For some 
 597 
unknown reason, the BRAF mutations occur only in sporadic, but not hereditary MSI-H tumors [52, 
53]. 
3. Although the MSI-H tumors are undifferentiated, they are usually characterized by 
occurrence of the disease. Specifically, MSI-H tumors show a relatively low rate of recurrence after 
surgery [54, 55]; accordingly, only 4% of locally advanced colorectal cancer have MSI-H 
phenotype [56, 58]. As a result, cases of MSI-H are extremely rare in the research related to 
metastatic cancer, so a direct clinical assessment of chemo-sensitivity is very complex. Most of the 
data on response to treatment for cases of MSI-H is derived from adjuvant therapy, where a reliable 
prognostic value of this parameter is not always possible. 
4. Sensitivity MMR-deficient cells to various anticancer drugs is the subject of numerous 
laboratory studies. It is important the natural cancer cells with MSI-H have an exceptionally high 
mutation rate, and therefore accumulates a considerable amount of "secondary" genetic lesions; 
depending on the spectrum of the target genes, the secondary damage may significantly alter the 
response to therapy [56, 59]. Furthermore, MMR inactivation of various genes, for example, MSH2 
and MLH1, can lead to various chemosensitivity models [62]. 
5. Most cases of preclinical studies indicate resistance MSI-H cell to 5-fluorouracil (5-FU) 
[56, 63]. MSI-H status is also associated with low sensitivity to Cisplatin, Carboplatin, 6-
thioguanine, however, these compounds aren’t used in any way used for the treatment of colorectal 
cancers [56, 61-63]. Whereas MMR-deficiency associated with insensitivity to Cisplatin [64, 65, 
66] and Carboplatin, Oxaliplatin. Several studies have shown particular sensitivity of MSI-H cells 
to Irinotecan; It was shown that the response to a topoisomerase I may be mediated by the presence 
of secondary mutations in the genes and MRE11 Rad50 [61]. Methotrexate is a selective inhibitor 
of the MSH2-deficient cells; MLH1-defective cells showed particular sensitivity to this compound 
[60, 62]. 
6. There is a consensus in the literature that the MSI-H patients do not use 5-fluorouracil-
based adjuvant therapy [67]. Some reports suggest even worse result compared with patients 
treated; PCTs may endanger the natural immune response to MSI-H cells [56, 68, 69]. Adjuvant 
chemotherapy in patients with hereditary colorectal cancer cases also showed no benefit from 5-FU 
[70]. Given the improved outlook MSI-H tumors, reputedly, adjuvant therapy should be omitted for 
the MSI-H colorectal cancer [56, 71, 72]. The combination of 5-FU with Oxaliplatin has been 
recently included in guidelines for adjuvant treatment of stage III colorectal cancer; since only a 
few MSI-H patients are currently available, it is still not possible to draw conclusions from existing 
data sets [73, 74]. Experiments with Irinotecan did not qualify this product for use in adjuvant 
therapy. However, analysis of a subgroup of patients with MSI-H showed that this particular 
category of patients may benefit from the addition of Irinotecan, Leucovorin and 5-Fluorouracil 
[75]. 
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7. Data on the use of chemotherapy for common MSI-H cancers are limited to small studies. 
Liang et al. [76] and Brueckl et al. [77] reported an improvement in the response of microsatellite 
unstable colorectal cancer to 5-fluorouracil. There are contradicting informations about the role of 
MSI status in determining the response to the combination therapy of 5-FU and Oxaliplatin [78-80]. 
Several reports have shown a greater incidence of MSI-H response to Irinotecan [81-83], although 
this claim has been challenged by a recent study, Kim et al. [84]. 
Given the above, MSI-H cancers correspond fairly uncommon clinical situation, expressed 
by the words "big tumor without distant metastases" (As opposed to when multiple distant 
metastases manifested, however primary tumor cannot be found at all). These cancers have the 
worst indicators of aggressive histology. They are poorly differentiated, have inf-γ  microscopic 
type of tumor infiltration, invade surrounding structures and can have multiple metastases in 
regional lymph nodes. Thus, after their removal, sufficient local, regional and overall result is 
affordable. 
Another, identified recently, genetic feature is the membership of the GC patients (less than 
5%) to the so-called "Angelina Jolie syndrome" [37]: genetically transferred mutations of one of the 
alleles of the BRCA-1 gene. Other diseases, related to this syndrome is breast cancer and ovarian 
cancer. Deletion of the remaining healthy allele (LOH - loss of heterosigosity, loss of 
heterozygosity) leads to the second type of hereditary gastric cancer (first - CDH1-associated). 
Because all hereditary cancers are dominantly inherited, this mutation appears at a relatively early 
age (before age 50). 
Also, as for the BRCA-associated breast cancer, the presence of the gene amplification 
means when RJ resistance to chemotherapeutic regimens based Taxanes [35] and Anthracyclines 
and sensitivity to Mitomycin C [34], Cisplatin and PARP-inhibitors (poly-ADP ribose polymerase 
inhibitors: PARIBAS [33]), the prospect of immunotherapy [40]. Her-2neu is positioned not only as 
a sensitivity factor to Trastuzumab therapy, therapy and sensitivity Epirubicin, Doxorubicin [25] 
liposomal doskorubitsinom. 
All of the above means the prospects of this trend analysis is not even in the laboratory and 
the field, the clinical setting. 
Immunohistochemical studies were performed to assess the expression of p53 protein 
products, VEGFR-3, Ki67 [6], Her2 \ new (Figure №4 and №5). One of the most important fact 
about the expression of Her2 \ new in stomach cancer is a lenient approach for the recognition of 
the marker positive, compared with breast cancer [30]. In our study, "++" marker was considered 
positive. While criterion "+++" is indispensable for breast cancer. 
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Fig. 4. Photomicrograph. Study of the expression of Her-2neu gene (with protein-erB-2 
Oncoprotein): «+++». 
 
 
Fig. 5. Fig-. Tissue image with the expression level of Ki67 Protein (MIB-1) - 80%. 
 
Ki67 - nuclear antigen, antibodies stain on which there arein case  cells in the proliferative 
phase of the cell cycle (G1, S, G2, M). It is also considered mitotic index. Penault-Llorca 
established [19] that patients whose tumors express the Ki67 more than 50% of the cells have a 
significant recurrence of the disease (not local, namely clinical recurrence). Ki67 expression study 
associated with sensitivity to Docetaxel [19]. In our study, it was considered positive expression in 
more than 30% of the cells. Reagent used - MIB-1 monoclonal antibody. 
VEGFR-3 and its sprout factor VEGF-C is associated with a very poor prognosis in gastric 
cancer [21]. Finally, VEGFR-3 is not a usual marker of the defective neoangiogenesis, which 
occurs in the tumor (vascular education without pericytes, endothelial cells only). VEGFR, as well 
as Ki67 can be used as a prediction factor for therapy: Bevacizumab assignment does not require 
execution of the analysis [20]. VEGFR-3 (VEGF-C) is a factor that can be used to analyze the 
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process of formation of new lymphatic vessels in the tumor itself and around it - because called 
lymphangiogenesis [23, 24]. In a normal situation VEGFR3 endothelium expressed early embryos. 
Honestly speaking, all the microscopic blood vessels in a tumor can be divided into two 
groups namely; 
1- The slit formation with a very thin wall  
2- 2-classical microscopic vessels.  
The first are microscopic lymph capillaries and contains lymph , second - blood capillaries 
(see Figures 6 and 7.). VEGFR3 Marker (see. Figure 8) related to the first lymph capillaries. It was 
also noted that the  expression of these tumor markers  is inversely proportional to the degree of 
dissemination through the blood capillaries. The tumors also had  a compensatory mechanism 
whereby  the tumor "turned" to create new lymphatic capillaries, through which it could spread in a 
process called dissemination .Failure of the lymphogenic dissemination the tumor turned into a 
hematogenous dissemination spreading through the blood capillaries. The presence of circulating 
tumor cells in the bloodstream does not mean directly the presence of hematogenous metastasis, but 
is a factor of poor prognosis [45, 46]. The properties of tumor microvessels can determine the 
effectiveness of a particular type of chemotherapy [47]. 
 
       
 
Fig. 6. Photomicrograph. Microscopic cracks unlike lymph and capillary vessels (at the top 
of the photo is visible the microscopic capillary with pronounced muscular component of the wall, 
just below - pronounced perivascular growth). 
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Fig. 7. Photomicrograph. Vascular Endothelial Growth Factor Receptor (VEGFR-3) (KLT 
9) + 
Promising, but not included in our study, the marker is Her1 or, as it is called today EGFR. 
We have one observation RJ mutation of the gene and expression of the corresponding protein 
product. 
 
 
Fig. 8. The photomicrograph. Immunohistochemical stains for Epidermal Growth Factor 
Receptor (EGFR) (HER-1), the expression level of "+". 
 
Materials and methods 
When analyzing the data via PubMed and Google Scholar search engine has received the 
following number of searches: 
`Gastric cancer her2 / new` - 165 (189) Links 
`Gastric cancer p53` - 2102 (210 000) links 
`Gastric cancer VEGFR` - 263 (19800) links 
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`Gastric cancer VEGF-C` - 137 (9960) references 
`Gastric cancer Ki-67` - 733 (31300) links 
`Gastric cancer p 53 Ki-67 VEGF` - 1 (6730) link 
`Gastric cancer p 53 Her2 VEGF` - 2 (43700) links 
`Gastric cancer p 53 Her2 ki-67` - 2 (4620) Links 
`Gastric cancer Her2 ki-67 VEGF` - 0 (2200) 
`Gastric cancer Her2 p53 ki-67 VEGF` - 0 (1740) 
`Gastric cancer Her2 / new p53 ki67 VEGF-C` - 0 (0) No 
In parentheses is the number of links on the subject on Google Scholar system. 
Thus, the selected combination of IHC markers in the study entitled "stomach cancer" seems 
to be original and at the same time, relevant. No studies indicated in the search PubMed and Google 
Scholar systems to include all 4 of these histochemical criterion for gastric cancer (Table 1). 
 
Table 1. Combination of two or more factors on PubMed search 
gastric cancer her2/new p53 VEGF Ki-67 
her2/new - 23 38 10 
p53 23 - 60 206 
VEGF 38 60 - 33 
Ki-67 10 206 33 - 
 
Paraffin blocks were used for immunohistochemical staining VEGF-C (KLT reagent 9). 
Thin sections were prepared, which were treated with a solution of 0.3% hydrogen peroxide for 10 
minutes at room temperature. For antigen detection, the sections were treated with sodium citrate 
pH 6.0 and placed in a microwave oven. During 12 hours at 4 ° C in  humid conditions we observed 
processing of primary antibodies: goat polyclonal VEGF-C antibody [1: 100, Biotechnology Santa 
Cruz, Santa USA]. Then the sections were washed three times in phosphate buffer solution for 2 
minutes, for 30 minutes at room temperature the solution was placed in horse reddish peroxidase 
(Envision, DAKO), labeled goat antibodies. Was added 3,3-diaminobenzidine. Normal goat IGG 
served as a negative control for the detection of VEGF-C. The degree of staining intensity was 
classified into four degrees: none (0), mild (1), moderate (2) and severe (3). 
Immunohistochemical staining procedure for the study of other markers differ almost only 
in the form of antibodies used: for the p53 - is a Do-7, m7001, DAKO, Glostrup, Denmark, for 
Her2 / new - it is a 2-erB-Oncoprotein, Ki-67 - reagent MIB- 1. 
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Although to fully genetically classify this group of patients (188 patients radically operated), 
it’s not enough data, of principal interest here is the relationship of histology and 
immunohistochemistry RJ. 
When assayed Chi-square relationship of the following characteristics were studied, 
resulting in a pair of histological / immunohistochemical (T / S) RJ structure. The main aim of the 
study was to monitor the trends, the ability to predict the value of the test in terms of the other, as 
well as mathematical modeling of the ability to use a new marker for clinical needs. "Necessity for 
the doctor is the exact mathematical value which intends looking forward it's PLR”. 
To evaluate the results obtained using standard descriptive statistical markers and evaluation 
of diagnostic tests: 
OR 
Sensitivity 
SpecificityPPV 
NPV 
PLR 
NLR 
 
OR - Odds ratio, is used to quantitatively describe how the presence or absence of the 
characteristic X correlated with the presence or absence of certain properties in the Z group. It’s of 
vital importance, if the OR is greater than 1, this relationship is positive. In biological studies OR 
rarely exceeds 10. As will be shown below, in our study a number of superiority OR 10 several 
times. For example, when it comes to the relationship between the value of the diagnostic VEGFR-
3 protein and tumor invasion into  microscopic vessels, OR-10 OR exceeded a hundred times. 
Sensitivity – It’s the proportion of positive predictor among those where it is really positive. 
For example, if the sensitivity of a diagnostic marker of 90% in 9/10 patients it will be changed 
(increased). 
Specificity – It’s the fraction of the normal value of the marker in an environment where it’s 
really normal. For example, if 80% specificity, in healthy patients marker 8.10 (diagnostic test) is 
normal. Both markers are considered as representing a diagnostic value if they represent a 
specificity greater than  75%. 
Using the following markers is a relatively recent innovation in medical research. If you 
make a selection of scientific works 10-20 years ago, these markers are usually not mentioned in 
them. 
PPV - Positive predictive value: positive predictive role or ability to predict a positive test 
result correctly. This is the proportion of patients with positive test results who were correctly 
diagnosed using the test diagnostic system. 
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NPV - Negative predictive value: negative predictive weight, the ability to predict a negative 
test result correct; the proportion of patients with negative test results, which investigated the 
diagnostic system (right) delivered a negative result. 
How to interpret the values obtained in the studies of these parameters. There is no clear 
answer in the literature can be found. However, one look at the interpretation of other similar 
criterion - the famous Pearson correlation coefficient [32] - has a significant response to these 
concerns. 
 
0.2 Very weak correlation 
0.2 - 0.5 A weak correlation 
0.5 - 0.7 Average correlation 
0.7 - 0.9 High correlation 
0,9 very high correlation 
 
However, it is much harder for the next group of evaluation criteria: PLR and NLR (See 
Table 2). 
 
Table 2. Mathematical interpretation of growth positive likelihood ratio. 
Likelihood Ratio Estimated change in [2] probability (%) * 
Values between 0 and 1 decrease the likelihood of having 
the disease  
 0.1 −45 
 0.2 −30 
 0.3 −25 
 0.4 −20 
 0.5 −15 
    1 0 
Values greater than 1 increases the probability of having 
the disease  
 2 +15 
 3 +20 
 4 +25 
 5 +30 
 6 +35 
 7  
 8 +40 
 9  
 10 +45 
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PLR - Positive likelihood ratio; the likelihood ratio of a positive test result. It is believed that 
if a likelihood ratio test of> 1, then the positive test is associated with the disease. If the likelihood 
ratio <1 - a positive result is associated with the absence of disease. In interpreting the plain 
language, PLR - it is mathematically predicted the diagnostic value of the newly discovered marker 
for clinical needs. 
NLR - Negative likelihood ratio; negative likelihood ratio test result. Negative diagnostic 
accuracy of the test. The lower the figure, the probability of a correct diagnosis of exclusion 
increases. 
Both of these indicators are directly related to the ability to predict the results of the test, i.e, 
importance of it for future clinical use, the importance in clinical practice. 
For example, the same early mentioned VEGFR-3 is the indicator "for further diagnostic 
clinical value» PLR = 89,333 with CI95% 15,867-1728,203, when it comes to its ability to "predict" 
the degree of hematogenous dissemination RJ. 
This relationship is reversed: the higher the (neo) lymphangiogenesis, the less there is 
hematogenous dissemination through the blood capillaries (Vo-V3) and vice versa. The lower (neo) 
lymphangiogenesis, the more tumor emboli in the capillaries (see. Table 5). 
Clinical conclusion may be, for example, keeping the concentration of VEGFR-3 
oncoprotein in gastrobioptatov? as one of the factors of preoperative planning vastness remove 
lymphatic nodes during operations on the stomach. Along with such important factors as the age of 
patients, the presence of severe co-morbidities, the degree of histological differentiation (there are 
reports that at signet cell cancer D2 less effective), already diagnosted hematogenous metastases 
(liver, ovaries), clinics installation, socio-economic constraints and so on.  
Calculations were made using mathematical power of online calculators available on the 
website http://statpages.info/. The results, depending on the level of accuracy to classify gray, blue 
and red zones, as shown in the table. The gray area - the result insignificant in terms of the further 
introduction into clinical practice, the blue zone - a significant result from a mathematical point of 
view, the red zone - a high-level results. For example, the odds ratio <1 is uninformative,> 1 
informative >> 1 highly informative. As can be seen from the attached table, highly informative 
results were not uncommon. 
 
Study proportion of patients with different tumor differentiation among patients with 
gastric cancer with different expression of IHC markers. 
Distribution of patients with gastric cancer expression of various factors was interesting 
from the point of view of expression of a marker in the group. p53 + (49,52%), VEGFR-3 + 
(43,56%), Ki67 + (33,33%), Her2 \ new + (62,22%) patients had a high and a moderate degree of 
histological differentiation from all IHC tests had positive expression. The high level erbB2 
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specifically for this sample of patients had a synonymous less aggressive course; in contrast to the 
other three indicators. Almost the same as that for breast cancer: Her2 \ new +, in contrast to the 
triple negative cancers, was nevertheless more favorable flow form (Her2, a genetic form of breast 
cancer, along with the luminal A and B types). 
Counting was carried out not from all 188 patients, but only on all the positive, and then by 
all the negative. p53 (22,89%), VEGFR-3- (35,63%), Ki67- (65,79%), Her2 \ new- (34,96%) 
patients had a high and a moderate degree of histological differentiation from all IHC tests, had no 
expression at all (see. table 3).  
 
Table 3. Study of histological and immunohistochemical markers in the forecast RJ: the 
degree of differentiation. 
 p53 VEGFR-3 Ki67 Her2\new 
+ - + - + - + - 
 g1g2 52 19 44 31 50 25 28 50 
g3g4 53 64 57 56 100 13 17 93 
р р˂0,0001 р=0,298 р˂0,0001 р=0,002 
 n CI 95% n CI 95% N CI 95% n CI 95% 
OR 3,305 1,667 6,600 1,394 0,742 2,626 0,260 0,114 0,585 3,064 1,452 6,509 
Чувстви-
тельность 
0,495 0,430 0,552 0,436 0,366 0,503 0,333 0,300 0,372 0,622 0,484 0,746 
Специфич-
ность 
0,771 0,688 0,843 0,644 0,563 0,722 0,342 0,211 0,496 0,650 0,607 0,689 
PPV 0,732 0,636 0,816 0,586 0,493 0,677 0,667 0,600 0,745 0,359 0,280 0,430 
NPV 0,547 0,488 0,538 0,496 0,433 0,556 0,115 0,071 0,167 0,845 0,789 0,896 
PLR 2,163 1,380 3,510 1,223 0,836 1,808 0,507 0,380 0,739 1,780 1,233 2,400 
NLR 0,655 0,532 0,828 0,877 0,689 1,127 1,949 1,265 3,323 0,581 0,369 0,849 
 
Research sometimes involves the fact that some results can not be explained at all, or not 
enough data. For example, it is clear why the mitotic index in most of the g1 + g2 patients was less 
than 30. These tumors are divide slowly, slower progress are ts more "benign". Obviously, because 
of the low potential of aggression, patients with VEGFR-3-positive tumors was less here. The same 
applies to another "genetic instability factor" - the protein p53. 
p53 + (50,48%), VEGFR-3 + (56,43%), Ki67 + (66,67%), Her2 \ new + (37,78%) patients 
had a low degree of or no histological differentiation from all the IHC test at all and at the sametime 
had positive expression being a clear indication of poor prognosis in clinical practice. More 
aggressive poorly differentiated tumors had accumulated large numbers of p53 proteins, VEGFR-3 
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and had much worse indicators of mitotic activity. IHC analysis is not genetic, and it is impossible 
to judge the extent of such a mutant p53, and about which the mutations in question. 
Immunohistochemistry gives only indirect information. If p53 protein becomes much, it means 
there is an increased expression of TP53 gene. This could be used, along with conventional 
histological markers. 
p53 (77,11%), VEGFR-3- (64,37%), Ki67- (34,21%), Her2 \ new- (65,04%) patients had a 
low degree of or no histological differentiation from all IHC tests, had no expression at all. Of the 
most impressive group of negative values of negative markers made that the absence of erbB2 
coincided with the malignancy of the tumor. 
 
RESEARCH AMONG  g1g2 and g3g4 ONCOPROTEINS. 
Total interest structure of each combination of markers among patients with different tumor 
differentiation in a number of cases in need of interpretation. Because here the ratio produced by all 
188 patients, and not separately from "positive" and individually a "negative", as it was done in the 
above. This was necessary in order to see the TS "General background" on which all the events 
occurred. 
 
Table 4. Study of histological and immunohistochemical markers in the forecast RJ: 
aggressive local growth. 
 p53 Т VEGFR-3 Т Ki67 Т Her2\new 
+ - + - + - + - 
 Т1, Т2 30 0 19 18 37 0 0 35 
Т3 19 0 0 20 25 0 13 14 
Т4 64 75 72 59 75 51 36 90 
Σ 113 75 91 97 137 51 49 139 
р р˂0,0001 р˂0,0001 р˂0,0001 р˂0,001 
 n CI 95% n CI 95% n CI 95% n CI 95% 
OR 27,108 3,803 547,425 21,111 2,495 466,305 18,870 2,655 380,367 0,066 0,003 0,473 
Чувствии-
тельн. 
0,265 0,226 0,274 0,950 0,768 0,997 0,270 0,238 0,277 -0,20 0,001 0,109 
Специфич
ность 
0,987 0,929 0,999 0,526 0,430 0,551 0,981 0,895 0,999 0,765 0,759 0,795 
PPV 0,968 0,825 0,998 0,514 0,415 0,539 0,974 0,856 0,990 0,028 0,001 0,151 
NPV 0,475 0,447 0,481 0,952 0,779 0,997 0,338 0,308 0,344 0,699 0,694 0,727 
PLR 20,177 3,168 397,774 2,006 1,347 2,223 14,044 14,044 275,279 0,085 0,004 0,53 
NLR 0,744 0,727 0,833 0,095 0,005 0,540 0,744 0,744 0,852 - - - 
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Vascular VEGFR-3 protein showed a positive reaction (due to the rarity of its expression 
level was considered positive, since 1+) g3g4 patients at 30.32%, 29.79% value almost coincided 
with the group, such as where it patients It was negative. A negative result - it is also a result. In the 
group with all the mitotic index were much more optimistic: the leader of Ki67 + g3g4 differed 
from the nearest pursuer, more than doubled, with the result of 53.19% of the patients. Almost the 
same thing happened to a group of Her2 \ new- g3g4 49,47%. 
Study proportion of patients with varying degrees of swelling of the stomach wall sprouting 
among patients with gastric cancer with different expression of IHC markers. 
Theoretically, p53, and VEGFR-3 could be used to increase the chance of performing more 
advanced operations in a long list of others, certainly more important the surgical criteria, such as 
infiltrative tumor growth (see. Table 7), "bad" histology (G3, G4 ), young age, and others. As we 
have seen above, the PLR value = 20.177 giving more than 45% increase in the probability of 
performing the combined operation, with an increase in the concentration of tumor p53 protein 
product. The same (14.044) is also valid in relation to factor Ki67 proliferation. 
 
Table 5. Study of histological and immunohistochemical markers in the forecast RJ: tumor 
emboli and invasion into the blood microvessels. 
 p53 V VEGFR-3 V Ki67 V Her2\new 
+ - + - + - + - 
 Vo 52 9 67 0 88 0 13 57 
V1 9 8 0 27 0 13 0 24 
V2 20 41 14 26 50 12 12 46 
 V3   31 18 0 54 12 13 13 23 
Σ 112 76 81 107 150 38 38 150 
р р˂0,0001 р˂0,0001 р˂0,0001 р=0,711 
 n CI 95% N CI 95% n CI 95% n CI 95% 
OR 6,452 2,776 15,411 512,07
1 
66,910 10719, 
582 
53,935 7,619 1084,5
91 
0,848 0,376 1,899 
Чувствит. 0,464 0,409 0,503 0,827 0,774 0,839 0,587 0,560 0,587 0,342 0,209 0,496 
Специф. 0,882 0,800 0,938 0,991 0,951 1,000 1,000 0,893 1,000 0,620 0,586 0,659 
PPV 0,852 0,751 0,923 0,985 0,922 0,999 1,000 0,954 1,000 0,186 0,114 0,269 
NPV 0,528 0,479 0,562 0,884 0,849 0,892 0,380 0,339 0,380 0,788 0,745 0,838 
PLR 3,921 2,049 8,164 89,333 15,867 1728,2
03 
22,88 3,935 442,03
8 
0,900 0,506 1,453 
NLR 0,608 0,530 0,738 0,174 0,161 0,237 0,424 0,408 0,516 1,061 0,765 1,348 
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In addition to determining the degree of differentiation of the primary tumor, the tumor 
incidence in the stomach, sprouting surrounding structure and so forth., Investigated lymph nodes 
by the number of groups № 1-16, the presence of tumor emboli in the capillary bed (V), the 
presence of residual tumor tissue (R) ( cm., table 6). 
 
Table 6. Study of histological and immunohistochemical markers in the forecast RJ: residual 
residual tumor disease. 
 p53 VEGFR-3 R Ki67 R Her2\new 
+ - + - + - + - 
 R- 96 74 98 10 141 28 42 129 
R+ 9 9 3 17 3 16 8 9 
р р=0,626 р˂0,0001 р˂0,0001 р=0,045 
 n CI 95% n CI 95% n CI 95% n CI 95% 
OR 1,297 0,445 3,781 7,933 2,080 35,505 26,875 6,709 125,10
8 
0,366 6,120 1,125 
Чувств
ит. 
0,914 0,876 0,953 0,970 0,925 0,992 0,979 0,949 0,994 0,840 0,760 0,917 
Специи
-фич. 
0,108 0,059 0,157 0,195 0,143 0,221 0,364 0,265 0,413 0,065 0,036 0,093 
PPV 0,565 0,541 0,589 0,583 0,556 0,596 0,834 0,809 0,847 0,246 0,222 0,268 
NPV 0,500 0,274 0,726 0,850 0,624 0,960 0,842 0,614 0,958 0,529 0,295 0,754 
PLR 1,025 0,931 1,131 1,206 1,080 1,273 1,539 1,291 1,695 0,899 0,789 1,010 
NLR 0,790 0,299 2,091 0,152 0,036 0,520 0,057 0,014 0,192 2,453 0,898 6,593 
 
 
Fig. 9. "Annular" enveloping microscopic vascular tumor tissue (arrow). 
 
The degree of vascular involvement was classified according JRSGC [31]: 
v0 - no vascular invasion; 
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v1 - the minimal vascular invasion; 
v2 - moderate vascular invasion; 
v3 - severe (severe) vascular invasion (see Figure. 9). 
 
Table 7. Study of histological and immunohistochemical markers in the forecast RJ: RJ type 
of infiltrating activities. 
 p53 VEGFR-3 Inf α, β 
Inf ϒ 
Ki67 Inf α, β 
Inf ϒ 
Her2\new 
+ - + - + - + - 
 Inf α, 
β 
75 41 79 27 122 10 25 90 
Inf ϒ 30 42 28 54 34 22 26 47 
р р=0,002 р˂0,0001 р˂0,0001 р=0,044 
 n CI 95% n CI 95% n CI 95% n CI 95% 
OR 2,561 1,341 4,907 5,643 2,865 11,191 7,894 3,183 19,954 0,502 0,248 1,014 
Sensitivity
. 
0,714 0,648 0,777 0,738 0,674 0,795 0,782 0,747 0,810 0,490 0,369 0,614 
Specificit
y. 
0,506 0,422 0,585 0,687 0,581 0,742 0,688 0,518 0,824 0,343 0,298 0,389 
PPV 0,647 0,586 0,703 0,745 0,680 0,803 0,924 0,883 0,957 0,217 0,164 0,272 
NPV 0,583 0,486 0,674 0,659 0,574 0,733 0,393 0,296 0,471 0,644 0,559 0,730 
PLR 1,446 1,120 1,872 2,215 1,609 3,085 2,503 1,552 4,601 0,746 0,526 1,003 
NLR 0,565 0,382 0,835 0,393 0,276 0,561 0,317 0,231 0,487 1,486 0,992 2,118 
 
The red color in the table marked with numbers, outstanding in terms of medical statistics 
biological research. For example, the odds ratio (the OR), equal to 27.108 (with a confidence 
interval of 3,803-547,425) for p53 and 21.111 (with a confidence interval= 2,495-466,305) is more 
characteristic of the mathematical accuracy of physical and engineering sciences. Significant 
indicators of sensitivity T / VEGFR-3, and the specificity of the T / p53, as well as indicators of T / 
p53 / the PPV, T / VEGFR-3 / the NPV, T / Ki67 / PLR consistent high quality of the study. At the 
same practical significance of the data "super-precision" dubious: it would be possible to try to 
predict the rate of tumor growth according to the criterion of T for different concentrations of 
oncoproteins, but it does not have enough data (see table 4.). 
The percentage of patients in the study had exponents ralichnye sprouting tumor gastric 
wall: p53 + (43,36%), VEGFR-3 + (20,88%), Ki67 + (27,00%), Her2 \ new + (0%) - during 
germination of the mucosa and submucosal tumor. p53 (0%), VEGFR-3- (39,18%), Ki67- (0%), 
Her2 \ new- (25,18%) - during germination mucosa and submucosa tumor. p53 + (56,64%), 
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VEGFR-3 + (79,12%), Ki67 + (73,00%), Her2 \ new + (100%) - germination serous membrane 
swelling and sprouting in adjacent organs (poor prognosis). p53 (100%), VEGFR-3- (60,82%), 
Ki67- (100%), Her2 \ new- (74,82%) - serosa tumor germination and sprouting into surrounding 
organs. In general, the faster the growth characteristic mestnodestruiruyuschy tumors with mutant 
p53 much greater mitotic index and high tendency to form microscopic vessels. 
 
Table 8. Study of histological and immunohistochemical markers in the forecast RJ: the 
presence of metastases in regional lymph nodes. 
 p53 VEGFR-3 Ki67 Her2\new 
+ - + - + - + - 
 No 55 22 55 29 11 17 26 58 
N1 22 23 42 15 42 19 17 27 
N2 22 44 16 28 43 29 15 39 
N3 0 0 1 2 20 7 0 6 
Σ 99 89 117 71 116 72 58 130 
р р˂0,0001 p=0,234 р=0,011 р=1,000 
 n CI 95% n CI 95% n CI 95% n CI 95% 
OR 3,807 1,952 7,472 1,447 0,766 2,738 0,339 0,137 0,830 1,009 0,516 1,969 
Чувствит. 0,556 0,485 0,618 0,482 0,421 0,541 0,095 0,055 0,140 0,448 0,337 0,563 
Специфи
т. 
0,753 0,674 0,822 0,608 0,513 0,699 0,764 0,700 0,836 0,554 0,504 0,605 
PPV 0,714 0,624 0,794 0,655 0,571 0,735 0,393 0,229 0,579 0,310 0,233 0,388 
NPV 0,604 0,541 0,659 0,433 0,365 0,497 0,344 0,315 0,376 0,692 0,630 0,756 
PLR 2,247 1,490 3,473 1,231 0,864 1,797 0,402 0,185 0,853 1,005 0,679 1,424 
NLR 0,590 0,465 0,763 0,851 0,656 1,129 1,185 1,029 1,349 0,996 0,723 1,315 
 
Germination throughout the T4 wall compared with earlier stages T1-T3. A glance at the 
table was enough to understand that oncoproteins concentration in locally advanced tumors were 
larger than in earlier. Perhaps this is due to the longer duration of the existence of a larger tumor, 
the accumulation of factors of aggression is slow. One is struck by the presence of the results of the 
"red zone": for example, the odds ratio >> 1, the positive likelihood ratio >> 1. 
The following table (Table 9) are marked in gray are mathematically "optimistic" markers of 
progression, which had, in our view, no practical application. They did not affect the frequency of 
microscopic residual tumor disease, metastasis to the lymph nodes (see. The data reflected in Table 
8), and the degree and type of infiltration of the gastric wall were more dependent on other factors. 
Black abandoned those relations, whose clinical significance is questionable. And finally, a dark red 
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- that can be used in planning further studies, with more advanced molecular genetic tests (MSI) 
inclusive. 
 
Table 9. Search diagnostically promising among the "optimistic" of pairs of markers. 
 
OR SENS SPEC PPV PLR NLR 
Т/p53 
27,108(3,803-
547,425) 
VEGFR-3/Т 
0,952(0,779-0,997) 
VEGFR-3/V  
0,991(0,951-
1,000) 
VEGFR-3/V  
0,985(0,922-
0,999) 
Ki67/Т 
14,044(14,04
4-275,279) 
Т/VEGF 
0,952(0,77
9-0,997) 
VEGFR-3/Inf 
5,643(2,865-
11,191) 
VEGFR-3/Т 
0,950(0,768-0,997) 
Ki67/V 
1,000(0,893-
1,000) 
Ki67/V 
1,000(0,954-
1,000) 
VEGFR-3/V 
89,333(15,86
7-1728,203) 
 
p53/V 
6,452(2,776-
15,411) 
VEGFR-3/R  
0,970(0,925-0,992) 
p53/Т 
0,987(0,929-
0,999) 
PPV/p53/Т 
0,968(0,825-
0,998) 
Ki67/V/PLR  
22,88 (3,935-
442,038) 
VEGFR-3/Т 
21,111(2,495-
466,305) 
Т/VEGF 
0,950(0,768-0,99) 
Т /p53 
0,987(0,929-
0,99) 
Т/p53 
0,968(0,825-
0,998) 
p53/Т  
20,177(3,168-
397,774) 
VEGFR-3/V  
512,071(66,910-
10719, 582) 
Ki67/R  
0,979(0,949-0,994) 
 Т/p53 
20,177(3,168-
397,774) 
p53/Т 
27,108(3,803-
547,425) 
 Т/Ki67 
14,044(14,04
4-275,279) 
Ki67/Inf 
7,894(3,183-
19,954) 
 
Ki67/V  
53,935(7,619-
1084,591) 
Ki67/R 
26,875(6,709-
125,108) 
VEGFR-3/R 
7,933(2,080-
35,505) 
Т/VEGF 
21,111(2,495-
466,305) 
 
Tracked trends in availability of oncogenetic markers and their importance in making  a 
fresh sense of perspective for further development of oncological sciences.   The abundance of 
available monthly appearing experimentals, practical, research results may be in the updated health 
information flow. Deepening practical oncology at the genetic, molecular sphere only briefly looks 
distracted from the realities of life scholasticism; immediately bringing new, more effective tools in 
the fight for the lives of patients in routine clinical practice. Exit "armchair science" in people is an 
event, useful for practicing oncologist and the patient. 
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Conclusions 
1. Modern rapid molecular genetic development of cancer science creates the preconditions 
for a more personal effect on the tumor. 
2. Generally, immunohistochemical and genetic data obtained when examining patients, 
sooner or later will result in a better understanding of the biology of gastric cancer, including 
planning of surgery in individual patients. 
3. Increase the availability of genome-sequencing to the next (3-5 years) time frame will 
lead the study of the genetics of cancer of the stomach and the individualization of treatment to a 
new level. 
 
References 
1. Gerstein ES, Lee SN, AB Ryabov et al. (2009) Comparative study immunosorbent matrix 
metalloproteinase-2, -7, -9 and tissue inhibitor type 2 in tumors and blood plasma of patients with 
gastric cancer. Bull. exp. biol. Med., 148 (12):. 660-663. 
2. McGee S. (2002) Simplifying Likelihood Ratios. J Gen Intern Med.,17(8): 647–650. 
3. Liao X., Lochhead P., Nishihara R. et al. (2012) Aspirin Use, Tumor PIK3CA Mutation, 
and Colorectal-Cancer Survival. N Engl J Med, 367: 1596-1606. 
4. Ayral-Kaloustian S., Salaski E.J. (2002) Protein farnesyltransferase inhibitors. Curr Med 
Chem., 9(10): 1003-1032. 
5. Amato M., Perrone G., Righi D. et al. (2016) HER2 Status in Gastric Cancer: Comparison 
between Primary and Distant Metastatic Disease. Pathol Oncol Res., 30: 1-7. 
6. Huang G., Chen S., Wang D., Wang R., Lin L., Chen S., Wang L., Huang Q. (2016) High 
Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma. Clin 
Lab. 62(1-2):141-53.  
7. Kanayama K., Imai H., Yoneda M., Hirokawa Y.S., Shiraishi T. (2016) Significant 
intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A 
comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer 
Sci. Apr;107(4):536-42. doi: 10.1111/cas.12886. Epub 2016 Feb 19.  
8. De Silva N., Schulz L., Paterson A., Qain W., Secrier M., Godfrey E., Cheow H., 
O'Donovan M., Lao-Sirieix P., Jobanputra M., Hochhauser D., Fitzgerald R., Ford H. (2015) 
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric 
adenocarcinoma. Br J Cancer. Nov 3;113(9):1305-12. doi: 10.1038/bjc.2015.342. Epub 2015 Oct 
20. PMID:26484410. 
9. Chen T., Xu X.Y., Zhou P.H.. (2016) Emerging molecular classifications and therapeutic 
implications for gastric cancer. Chin J Cancer. May 27;35(1):49. doi: 10.1186/s40880-016-0111-5. 
Review. PMID:27233623. 
 614 
10. Nadauld L.D., Ford J.M.. (2013) Molecular profiling of gastric cancer: toward 
personalized cancer medicine. J Clin Oncol. 31(7):838–839. doi: 10.1200/JCO.2012.47.1714. 
11. Stahl P., Seeschaaf C., Lebok P., Kutup A., Bockhorn M., Izbicki J.R., et al. (2015) 
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC 
Gastroenterol. 15:7.  
12. Zhang W. (2014) TCGA divides gastric cancer into four molecular subtypes: 
implications for individualized therapeutics. Chin J Cancer. 33(10):469–470. 
13. Murphy G., Pfeiffer R., Camargo M.C., Rabkin C.S. (2009) Meta-analysis shows that 
prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. 
Gastroenterology. 137(3):824–833.  
14. Burke A.P., Yen T.S., Shekitka K.M., Sobin L.H. (1990) Lymphoepithelial carcinoma of 
the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol. 
3(3):377–380.  
15. Kaneda A., Matsusaka K., Aburatani H., Fukayama M. (2012) Epstein-Barr virus 
infection as an epigenetic driver of tumorigenesis. Cancer Res. 72(14):3445–3450. doi: 
10.1158/0008-5472.CAN-11-3919. 
16. Chen T., Sun Y., Ji P., Kopetz S., Zhang W. (2015) Topoisomerase IIα in chromosome 
instability and personalized cancer therapy. Oncogene. 34(31):4019–4031. doi: 
10.1038/onc.2014.332. 
17. Cidon E.U., Ellis S.G., Inam Y., Adeleke S., Zarif S., Geldart T. (2013) Molecular 
targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) 
5(1):64–91. doi: 10.3390/cancers5010064. 
18. Jong Gwang Kim. (2013) Molecular targeted therapy for advanced gastric cancer. 
Korean J Intern Med. 28(2): 149–155. PMCID: PMC3604602. 
19. Penault-Llorca F., André F., Sagan C., Lacroix-Triki M., Denoux Y., Verriele V., 
Jacquemier J., Baranzelli M.C., Bibeau F., Antoine M., Lagarde N., Martin A.L., Asselain B., 
Roché H. (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive 
breast cancer. J Clin Oncol. 27(17):2809-15. doi: 10.1200/JCO.2008.18.2808. Epub 2009 Apr 20. 
20. Tsai H.L., Lin C.H., Huang C.W., Yang I.P., Yeh Y.S., Hsu W.H., Wu J.Y., Kuo C.H., 
Tseng F.Y., Wang J.Y. (2015) Decreased peritherapeutic VEGF expression could be a predictor of 
responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol. 
1;8(2):1900-10.  
21. Weiguo Cao, Rong Fan, Weiping Yang, Yunlin Wu. (2014) VEGF-C expression is 
associated with the poor survival in gastric cancer tissue. Tumor Biology. Volume 35, Issue 4, pp 
3377-3383. 
 615 
22. Hong-Feng Gou, Xin-Chuan Chen, Jiang Zhu, Ming Jiang, Yu Yang, Dan Cao, and Mei 
Hou. (2011) Expressions of COX-2 and VEGF-C in gastric cancer: correlations with 
lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011; 30(1): 14. PMCID: 
PMC3037339 (полнотекстовая). 
23. Makoto Ishikawa, Joji Kitayama, Shinsuke Kazama and Hirokazu Nagawa (2016). 
Expression of  Vascular Endothelial Growth Factor C and D (VEGF-C and -D) is an Important Risk 
Factor for Lymphatic Metastasis in Undifferentiated Early Gastric Carcinoma. Japanese Journal of 
Clinical Oncology. Volume 33, Issue 1. Pp. 21-27 (полнотекстовая). 
24. Yutaka Yonemura , Yoshio Endo, Kayoko Tabata, Taiichi Kawamura, Hyo-Yung Yun, 
Etsurou Bandou, Takuma Sasaki, Masahiro Miura  (2005).  Role of VEGF-C and VEGF-D in 
lymphangiogenesis in gastric cancer. International Journal of Clinical Oncology. Volume 10, Issue 
5, pp 318-327. 
25. Angela Moliterni, Sylvie Ménard, Pinuccia Valagussa, Elia Biganzoli, Patrizia Boracchi, 
Andrea Balsari, Patrizia Casalini, Gorana Tomasic, Ettore Marubini, Silvana Pilotti and Gianni 
Bonadonna (2003). HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for 
Resectable Breast Cancer. doi: 10.1200/JCO.2003.04.021. JCO vol. 21 no. 3 458-462 
(полнотекстовая - http://jco.ascopubs.org/content/21/3/458.full). 
26. Ananiev J., Gulubova M., Manolova I., Tchernev G. (2011). Prognostic significance of 
HER2/neu expression in gastric cancer. Article (PDF Available) in Wiener klinische 
Wochenschrift 123(13-14):450-4. 
27. Jørgensen J. T., Hersom M. (2012)  HER2 as a Prognostic Marker in Gastric Cancer - A 
Systematic Analysis of Data from the Literature. J Cancer 3:137-144. doi:10.7150/jca.4090 
(полнотекстовая).  
28. Gravalos C.; Jimeno A. (2008) HER2 in Gastric Cancer: A New Prognostic Factor and a 
Novel Therapeutic Target. Ann Oncol. 19(9):1523-1529 (полнотекстовая). 
29.  Rüschoff J., et al. (2012) HER2 testing in gastric cancer: a practical approach. Modern 
Pathology 25, 637–650. 
30. Sheffield B.S., Garratt J., Kalloger S.E., Li-Chang H.H., Torlakovic E.E., Gilks C.B., 
Schaeffer D.F. (2014) HER2/neu testing in gastric cancer by immunohistochemistry: assessment of 
interlaboratory variation. Arch Pathol Lab Med. 138(11):1495-502. doi: 10.5858/arpa.2013-0604-
OA. 
31. Japanese Classification of Gastric Carcinoma – 2nd English Edition – Japanese Gastric 
Cancer Association. Gastric Cancer (1998) 1: 10-24 
32. Zhang Y.Y., Gu K.S., Wu H.Y., Yang F., Bu L.J., Zhao C.C., Zhang Y.R. (2015) 
Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with 
 616 
gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Genet Mol Res. 14(4):15921-
9. (полнотекстовая). 
33. Munroe M., Kolesar J. (2016)  Olaparib for the treatment of BRCA-mutated advanced 
ovarian cancer. Am J Health Syst Pharm. 15;73(14):1037-41.  
34. Moiseyenko V.M., Chubenko V.A., Moiseyenko F.V., Zhabina A.S., Gorodnova T.V., 
Komarov Y.I., Bogdanov A.A., Sokolenko A.P., Imyanitov E.N. (2014) Evidence for clinical 
efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 
mutation. Med Oncol. 31(10):199. doi: 10.1007/s12032-014-0199-x. Epub 2014 Sep 4.  
35. Kriege M., Jager A., Hooning M.J., Huijskens E., Blom J., van Deurzen C.H., Bontenbal 
M., Collee J.M., Menke-Pluijmers M.B., Martens J.W., Seynaeve C. (2012) The efficacy of taxane 
chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer. 
118(4):899-907.  
36. Alessandro Lugli, Inti Zlobec, Gad Singer, Andrea Kopp Lugli, Luigi M Terracciano 
and Robert M Genta*. (2007) Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to 
staging, pathogenesis, and etiology. Nature Clinical Practice Gastroenterology & Hepatology 4, 52-
57. 
37. James P.A., Mitchell G., Bogwitz M., Lindeman G.J. (2013) The Angelina Jolie effect. 
Med J Aust. 18;199(10):646. 
38. Kawata S., Yashima K., Yamamoto S., Sasaki S., Takeda Y., Hayashi A., Matsumoto 
K., Kawaguchi K., Harada K., Murawaki Y. (2015) AID (activation-induced cytidine deaminase), 
p53 and MLH1 expression in early gastric neoplasms and the correlation with the background 
mucosa. Oncol Lett. 10(2):737-743.  
39. Li Z., Lai Y., Sun L., Zhang X., Liu R., Feng G., Zhou L., Jia L., Huang X., Kang Q., 
Lin D., Gao J., Shen L. (2016) PD-L1 expression is associated with massive lymphocyte infiltration 
and histology in gastric cancer. Hum Pathol. 31. pii: S0046-8177(16)30093-4. 
40. Nanda R., Chow L.Q., Dees E.C., Berger R., Gupta S., Geva R., Pusztai L., Pathiraja K., 
Aktan G., Cheng J.D., Karantza V., Buisseret L. (2016) Pembrolizumab in Patients With Advanced 
Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2. pii: JCO648931. 
[Epub ahead of print] 
41. Muro K., Chung H.C., Shankaran V., Geva R., Catenacci D., Gupta S., Eder J.P., Golan 
T., Le D.T., Burtness B., McRee A.J., Lin C.C., Pathiraja K., Lunceford J., Emancipator K., Juco J., 
Koshiji M., Bang Y.J. (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric 
cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17(6):717-26.  
42. Shigeyasu K., Nagasaka T., Mori Y., Yokomichi N., Kawai T., Fuji T., Kimura K., 
Umeda Y., Kagawa S., Goel A., Fujiwara T. (2015) Clinical Significance of MLH1 Methylation 
 617 
and CpG Island Methylator Phenotype as Prognostic Markers in Patients with Gastric Cancer. PLoS 
One. 10(6):e0130409. 
43. He D., Zhang Y.W., Zhang N.N., Zhou L., Chen J.N., Jiang Y., Shao C.K. (2015) 
Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr 
virus-associated gastric carcinomas. Med Oncol. 32(4):92.  
44. YING HUANG, PUYUAN W.U., BAORUI LI.U, and JUAN D.U. (2016) Successful 
personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA 
expression level: A case report. Oncol Lett. 11(6): 4183–4186. PMCID: PMC4888084. 
45. Qiao G.L., Qi W.X., Jiang W.H., Chen Y., Ma L.J. (2016) Prognostic significance of 
circulating tumor cells in esophageal carcinoma: a meta-analysis. Onco Targets Ther. 9:1889-97.  
46. Tsai W.S., Chen J.S., Shao H.J., Wu J.C., Lai J.M., Lu S.H., Hung T.F., Chiu Y.C., You 
J.F., Hsieh P.S., Yeh C.Y., Hung H.Y., Chiang S.F., Lin G.P., Tang R., Chang Y.C. (2016) 
Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic 
Marker for Distant Metastasis in Non-Metastatic Patients. Sci Rep. 6:24517.  
47. Gao Z.H., Wang Q.Q. (2015) Curative effect of paclitaxel and cisplatin combined 
chemotherapy on cervical cancer and its relation with tissue micro vascular and lymphatic vessels 
density. Pak J Pharm Sci. 28(5 Suppl):1849-52. 
48. Guastadisegni C., Colafranceschi M., Ottini L., Dogliotti E. (2010) Microsatellite 
instability as a marker of prognosis and response to therapy: a meta analysis of colorectal cancer 
survival data // Europ. J. Cancer. Vol.46. – P.2788-2798. 
49. Vilar E., Gruber S.B. (2010) Microsatellite instability in colorectal cancer - the stable 
evidence // Nat. Rev. Clin. Oncol. Vol.7. – P.153-162. 
50. Imyanitov E.N., Moiseyenko V.M. (2011) Drug therapy for hereditary cancers. Hered 
Cancer Clin Pract. 9(1):5.  
51. Boland C.R., Goel A. (2010) Microsatellite instability in colorectal cancer. 
Gastroenterology. 2010;138:2073–2087. doi: 10.1053/j.gastro.2009.12.064. [PMC free article]  
52. Vilar E., Gruber S.B. (2010)  Microsatellite instability in colorectal cancer-the stable 
evidence. Nat Rev Clin Oncol. 7:153–162.  
53. Clark A.J., Barnetson R., Farrington S.M., Dunlop M.G. (2004) Prognosis in DNA 
mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer. 
2004;3:85–91.  
54. Popat S., Hubner R., Houlston R.S. (2005) Systematic review of microsatellite 
instability and colorectal cancer prognosis. J Clin Oncol. 23:609–618.  
55. Guastadisegni C., Colafranceschi M., Ottini L., Dogliotti E. (2010) Microsatellite 
instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer 
survival data. Eur J Cancer. 46:2788–2798. doi: 10.1016/j.ejca.2010.05.009. [PubMed] [Cross Ref] 
 618 
56. Hewish M., Lord C.J., Martin S.A., Cunningham D., Ashworth A. (2010)  Mismatch 
repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 7:197–
208. doi: 10.1038/nrclinonc.2010.18. [PubMed] [Cross Ref] 
57. Laghi L., Bianchi P., Malesci A. (2008) Differences and evolution of the methods for the 
assessment of microsatellite instability. Oncogene. 27:6313–6321. doi: 10.1038/onc.2008.217. 
[PubMed] [Cross Ref] 
58. Perucho M. (1999) Correspondence re: C.R. Boland et al., A National Cancer Institute 
workshop on microsatellite instability for cancer detection and familial predisposition: development 
of international criteria for the determination of microsatellite instability in colorectal cancer. 
Cancer Res., 58: 5248-5257. Cancer Res. 1999;59:249–256. [PubMed] 
59. Vilar E., Scaltriti M., Balmaña J., Saura C., Guzman M., Arribas J., Baselga J., 
Tabernero J. (2008) Microsatellite instability due to hMLH1 deficiency is associated with increased 
cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer. 99:1607–1612.  
60. Martin S.A., McCarthy A., Barber L.J., Burgess D.J., Parry S., Lord C.J., Ashworth A. 
(2009) Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with 
defects in the DNA mismatch repair gene MSH2. EMBO Mol Med. 1:323–337. doi: 
10.1002/emmm.200900040.  
61. Valentini A.M., Armentano R., Pirrelli M., Caruso M.L. (2006) Chemotherapeutic 
agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer 
Treat Rev. 32:607–618. doi: 10.1016/j.ctrv.2006.08.001.  
62. Papouli E., Cejka P., Jiricny J. (2004) Dependence of the cytotoxicity of DNA-damaging 
agents on the mismatch repair status of human cells. Cancer Res. 64:3391–3394. doi: 
10.1158/0008-5472.CAN-04-0513.  
63. Yamane K., Schupp J.E., Kinsella T.J. (2007) BRCA1 activates a G2-M cell cycle 
checkpoint following 6-thioguanine-induced DNA mismatch damage. Cancer Res. 67:6286–6292. 
doi: 10.1158/0008-5472.CAN-06-2205.  
64. Fink D., Zheng H., Nebel S., Norris P.S., Aebi S., Lin T.P., Nehmé A., Christen R.D., 
Haas M., MacLeod C.L., Howell S.B. (1997) In vitro and in vivo resistance to cisplatin in cells that 
have lost DNA mismatch repair. Cancer Res. 57:1841–1845.  
65. Martin S.A., Hewish M., Sims D., Lord C.J., Ashworth A. (2011) Parallel high 
throughput RNA interference screens identify PINK1 as a potential therapeutic target for the 
treatment of DNA mismatch repair deficient cancers. Cancer Res. 71:1836–1848. doi: 
10.1158/0008-5472.CAN-10-2836.  
66. Martin S.A., McCabe N., Mullarkey M., Cummins R., Burgess D.J., Nakabeppu Y., Oka 
S., Kay E., Lord C.J., Ashworth A. (2010) DNA polymerases as potential therapeutic targets for 
 619 
cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 17:235–248. 
doi: 10.1016/j.ccr.2009.12.046.  
67. des Guetz G., Schischmanoff O., Nicolas P., Perret G.Y., Morere J.F, Uzzan B. (2009) 
Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A 
systematic review with meta-analysis. Eur J Cancer. 45:1890–1896.  
68. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., 
Hamilton S.R., Laurent-Puig P., Gryfe R., Shepherd L.E., Tu D., Redston M., Gallinger S. (2003) 
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant 
chemotherapy for colon cancer. N Engl J Med. 349:247–257. doi: 10.1056/NEJMoa022289.  
69. Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., 
French A.J., Kabat B., Foster N.R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz 
J.F., Sinicrope F., Gallinger S. (2010) Defective mismatch repair as a predictive marker for lack of 
efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 28:3219–3226. doi: 
10.1200/JCO.2009.27.1825.  
70. de Vos tot Nederveen Cappel W.H., Meulenbeld H.J., Kleibeuker J.H., Nagengast F.M., 
Menko F.H., Griffioen G., Cats A., Morreau H., Gelderblom H., Vasen H.F. (2004) Survival after 
adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int 
J Cancer. 109:468–471. doi: 10.1002/ijc.11712.  
71. Sinicrope F.A., Sargent D.J. (2009) Clinical implications of microsatellite instability in 
sporadic colon cancers. Curr Opin Oncol. 21:369–373. doi: 10.1097/CCO.0b013e32832c94bd. 
72. de la Chapelle A., Hampel H. (2010) Clinical relevance of microsatellite instability in 
colorectal cancer. J Clin Oncol. 28:3380–3387. doi: 10.1200/JCO.2009.27.0652.  
73. Kim S.T., Lee J., Park S.H., Park J.O., Lim H.Y., Kang W.K., Kim J.Y., Kim Y.H., 
Chang D.K., Rhee P.L., Kim D.S., Yun H., Cho Y.B., Kim H.C., Yun S.H., Lee W.Y., Chun H.K., 
Park Y.S. (2010) Clinical impact of microsatellite instability in colon cancer following adjuvant 
FOLFOX therapy. Cancer Chemother Pharmacol. 66:659–667.  
74. Zaanan A., Cuilliere-Dartigues P., Guilloux A., Parc Y., Louvet C., de Gramont A., Tiret 
E., Dumont S., Gayet B., Validire P., Fléjou JF., Duval A., Praz F. (2010) Impact of p53 expression 
and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-
fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 21:772–780.  
75. Bertagnolli M.M., Niedzwiecki D., Compton C.C., Hahn H.P., Hall M., Damas B., 
Jewell S.D., Mayer R.J., Goldberg R.M., Saltz L.B., Warren R.S., Redston M. (2009) Microsatellite 
instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and 
leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 
27:1814–1821. doi: 10.1200/JCO.2008.18.2071.  
 620 
76. Liang J.T., Huang K.C., Lai H.S., Lee P.H., Cheng Y.M., Hsu H.C., Cheng A.L., Hsu 
C.H., Yeh K.H., Wang S.M., Tang C., Chang K.J. (2002) High-frequency microsatellite instability 
predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage 
IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer. 101:519–525.  
77. Brueckl W.M., Moesch C., Brabletz T., Koebnick C., Riedel C., Jung A., Merkel S., 
Schaber S., Boxberger F., Kirchner T., Hohenberger W., Hahn E.G., Wein A. (2003) Relationship 
between microsatellite instability, response and survival in palliative patients with colorectal cancer 
undergoing first-line chemotherapy. Anticancer Res. 23:1773–1777.  
78. des Guetz G., Mariani P., Cucherousset J., Benamoun M., Lagorce C., Sastre X., Le 
Toumelin P., Uzzan B., Perret G.Y., Morere J.F., Breau J.L., Fagard R., Schischmanoff P.O. (2007) 
Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. 
Anticancer Res. 27:2715–2719.  
79. Müller C.I., Schulmann K., Reinacher-Schick A., Andre N., Arnold D., Tannapfel A., 
Arkenau H., Hahn S.A., Schmoll S.H., Porschen R., Schmiegel W., Graeven U. (2008) AIO 
Colorectal Study Group. Predictive and prognostic value of microsatellite instability in patients with 
advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line 
chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 23:1033–1039.  
80. Kim S.T., Lee J., Park S.H., Park J.O., Lim H.Y., Kang W.K., Kim J.Y., Kim Y.H., 
Chang D.K., Rhee P.L., Kim D.S., Yun H., Cho Y.B., Kim H.C., Yun S.H., Chun H.K., Lee W.Y., 
Park Y.S. (2010) The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line 
chemotherapy as in recurrent or metastatic colon cancer. Med Oncol. 27:1277–1285. doi: 
10.1007/s12032-009-9374-x.  
81. Fallik D., Borrini F., Boige V., Viguier J., Jacob S., Miquel C., Sabourin J.C., Ducreux 
M., Praz F. (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan 
in patients with advanced colorectal cancer. Cancer Res. 63:5738–5744. 
82. Charara M., Edmonston T.B., Burkholder S., Walters R., Anne P., Mitchell E., Fry R., 
Boman B., Rose D., Fishel R., Curran W., Palazzo J. (2004) Microsatellite status and cell cycle 
associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 
chemotherapy and radiotherapy. Anticancer Res.;24:3161–3167. 
83. Bendardaf R., Lamlum H., Ristamäki R., Korkeila E., Syrjänen K., Pyrhönen S. (2007) 
Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan 
chemotherapy in patients with advanced colorectal cancer. Tumour Biol. 28:212–220. doi: 
10.1159/000107417.  
84. Kim J.E., Hong Y.S., Ryu M.H., Lee J.L., Chang H.M., Lim S.B., Kim J.H., Jang S.J., 
Kim M.J., Yu C.S., Kang Y.K., Kim J.C., Kim T.W. (2011) Association between deficient 
 621 
mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon 
cancer. Cancer Sci. in press.  
